Yangtze River Pharmaceutical Group Co Ltd 2024 SR
The report outlines Yangtze River Pharmaceutical Group's sustainability progress in 2024, highlighting its 'dual-health' strategy and digital transformation initiatives. Key achievements include reducing carbon emissions by 12,000 tons, establishing Jiangsu's first 'Zero-Waste Group' in the pharmaceutical sector, and maintaining 80 standardized TCM planting bases. The company advanced its R&D with over 20 new drugs in clinical stages and earned a 7-star EFQM certification. Socially, the Group donated over RMB 300 million to public welfare over four years and supported rural revitalization through its extensive TCM supply chain.
Company: Yangtze River Pharmaceutical Group Co Ltd
Year: 2024
Type: SR
Pages: 60
Yangtze River Pharmaceutical Group Co Ltd
Environmental, Social And Governance Report
The report outlines Yangtze River Pharmaceutical Group's sustainability progress in 2024, highlighting its 'dual-health' strategy and digital transformation initiatives. Key achievements include reducing carbon emissions by 12,000 tons, establishing Jiangsu's first 'Zero-Waste Group' in the pharmaceutical sector, and maintaining 80 standardized TCM planting bases. The company advanced its R&D with over 20 new drugs in clinical stages and earned a 7-star EFQM certification. Socially, the Group donated over RMB 300 million to public welfare over four years and supported rural revitalization through its extensive TCM supply chain.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women in Management
Workplace Fatalities
Employees